Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically confirmed metastatic melanoma, surgically incurable and unresectable
Stage IIIc or IV (AJCC)

- Prior treatment for metastatic melanoma allowed; >/= 28 days must be elapsed since
previous systemic treatment prior to first administration of study drug

- Positive BRAF V600E mutation result (by Roche CoDx test)

- ECOG performance status 0-1

- Adequate hematologic, renal and liver function

- Body Mass Index (BMI) 18 to 32 kg/m2 inclusive

Exclusion Criteria:

- Active CNS lesions

- History of or known spinal cord compression, or carcinomatous meningitis

- Anticipated or ongoing administration of any anticancer therapies other than those
administered in this study

- Refractory nausea or vomiting, or other medical conditions that are capable of
altering the absorption, metabolism or elimination of the study drug

- Known clinically significant active infection

- Known HIV positivity or AIDS-related illness, active HBV, or active HCV

- Previous malignancy within the past 5 years, except for basal or squamous cell
carcinoma of the skin, melanoma in situ, and carcinoma in situ of the cervix

- Clinically significant cardiovascular disease or incident within the 6 months prior
to study drug administration

- Patients who have had at least one dose of study drug (RO5185426 or comparator) in a
clinical trial that includes RO5185426